Research programme: antibody therapeutics - Adimab/Sanofi
Latest Information Update: 10 Feb 2015
At a glance
- Originator Adimab; Sanofi
- Class Antibodies; Bispecific antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 06 Feb 2015 Early research in Undefined indication in USA (unspecified route)